The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pet Cancer Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
The global Pet Cancer Therapeutics market size is expected to reach US$ 675.4 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Pet Cancer Therapeutics in various end use industries. The expanding demands from the Lymphoma, Mast Cell Cancer, Melanoma and Mammary, are propelling Pet Cancer Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at % CAGR for the next seven-year period.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 40%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pet Cancer Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pet Cancer Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pet Cancer Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pet Cancer Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pet Cancer Therapeutics covered in this report include Aratana Therapeutics, Inc, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc, VetDC, Inc, Karyopharm Therapeutics, Inc, Rhizen Pharmaceutical SA and Regeneus Ltd., etc.
The global Pet Cancer Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis
VetiVax
Ngelheim International GmbH
Elanco
Merial Inc
ELIAS Animal Health
Global Pet Cancer Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pet Cancer Therapeutics market, Segment by Type:
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy
Global Pet Cancer Therapeutics market, by Application
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pet Cancer Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer.
The global Pet Cancer Therapeutics market size is expected to reach US$ 675.4 million by 2029, growing at a CAGR of 7.9% from 2023 to 2029. The market is mainly driven by the significant applications of Pet Cancer Therapeutics in various end use industries. The expanding demands from the Lymphoma, Mast Cell Cancer, Melanoma and Mammary, are propelling Pet Cancer Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at % CAGR for the next seven-year period.
Pet medical care is the second largest segment in pet industry. In the UK, annual spending on veterinary and other pet services has risen from £2.6bn in 2015 to £4bn in 2021, a 54% increase in just six years. According to Vetnosis, the value of the global animal health industry will increase by 12% to $38.3 billion in 2021. White Paper on China's Pet Healthy Consumption of JD shows that in 2023, there are 13.09 million pets entering middle age and old age. And pet aging is expected to be seen in the next few years. Changes in the age structure of pets will further bring about the development of the pet medical industry. According to the data of the 2022 China Pet Medical Industry White Paper, from the perspective of market size, the scale of China's pet medical market is about ¥67.5 billion, accounting for about 22.5% of the entire pet industry. From the perspective of hospital operation time, pet hospitals within 5 years accounted for about 73%. About 11% of the pet hospitals have been in operation for more than 10 years. From the perspective of hospital turnover, nearly 40% of the hospitals have increased their annual turnover year-on-year, and the growth rate is mainly within 40%.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pet Cancer Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pet Cancer Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pet Cancer Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pet Cancer Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pet Cancer Therapeutics covered in this report include Aratana Therapeutics, Inc, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc, VetDC, Inc, Karyopharm Therapeutics, Inc, Rhizen Pharmaceutical SA and Regeneus Ltd., etc.
The global Pet Cancer Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Aratana Therapeutics, Inc
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
Morphogenesis, Inc
VetDC, Inc
Karyopharm Therapeutics, Inc
Rhizen Pharmaceutical SA
Regeneus Ltd.
Oasmia Pharmaceuticals AB
Zoetis
VetiVax
Ngelheim International GmbH
Elanco
Merial Inc
ELIAS Animal Health
Global Pet Cancer Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pet Cancer Therapeutics market, Segment by Type:
Chemotherapy
Targeted Therapy
Combination Therapy
Immunotherapy
Global Pet Cancer Therapeutics market, by Application
Lymphoma
Mast Cell Cancer
Melanoma
Mammary
Squamous Cell Cancer
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pet Cancer Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Pet Cancer Therapeutics
1.1 Pet Cancer Therapeutics Market Overview
1.1.1 Pet Cancer Therapeutics Product Scope
1.1.2 Pet Cancer Therapeutics Market Status and Outlook
1.2 Global Pet Cancer Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pet Cancer Therapeutics Market Size by Region (2018-2029)
1.4 Global Pet Cancer Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Pet Cancer Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pet Cancer Therapeutics Market Size (2018-2029)
1.6.1 North America Pet Cancer Therapeutics Market Size (2018-2029)
1.6.2 Europe Pet Cancer Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Pet Cancer Therapeutics Market Size (2018-2029)
1.6.4 Latin America Pet Cancer Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Pet Cancer Therapeutics Market Size (2018-2029)
2 Pet Cancer Therapeutics Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Targeted Therapy
2.1.3 Combination Therapy
2.1.4 Immunotherapy
2.2 Global Pet Cancer Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pet Cancer Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Pet Cancer Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pet Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pet Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pet Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pet Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pet Cancer Therapeutics Revenue Breakdown by Type (2018-2029)
3 Pet Cancer Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Lymphoma
3.1.2 Mast Cell Cancer
3.1.3 Melanoma
3.1.4 Mammary
3.1.5 Squamous Cell Cancer
3.1.6 Others
3.2 Global Pet Cancer Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pet Cancer Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Pet Cancer Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pet Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pet Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pet Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pet Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pet Cancer Therapeutics Revenue Breakdown by Application (2018-2029)
4 Pet Cancer Therapeutics Competition Analysis by Players
4.1 Global Pet Cancer Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pet Cancer Therapeutics as of 2022)
4.3 Date of Key Players Enter into Pet Cancer Therapeutics Market
4.4 Global Top Players Pet Cancer Therapeutics Headquarters and Area Served
4.5 Key Players Pet Cancer Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Pet Cancer Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Aratana Therapeutics, Inc
5.1.1 Aratana Therapeutics, Inc Profile
5.1.2 Aratana Therapeutics, Inc Main Business
5.1.3 Aratana Therapeutics, Inc Pet Cancer Therapeutics Products, Services and Solutions
5.1.4 Aratana Therapeutics, Inc Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Aratana Therapeutics, Inc Recent Developments
5.2 AB Science
5.2.1 AB Science Profile
5.2.2 AB Science Main Business
5.2.3 AB Science Pet Cancer Therapeutics Products, Services and Solutions
5.2.4 AB Science Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 AB Science Recent Developments
5.3 Boehringer Ingelheim International GmbH
5.3.1 Boehringer Ingelheim International GmbH Profile
5.3.2 Boehringer Ingelheim International GmbH Main Business
5.3.3 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Products, Services and Solutions
5.3.4 Boehringer Ingelheim International GmbH Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Zenoaq Recent Developments
5.4 Zenoaq
5.4.1 Zenoaq Profile
5.4.2 Zenoaq Main Business
5.4.3 Zenoaq Pet Cancer Therapeutics Products, Services and Solutions
5.4.4 Zenoaq Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Zenoaq Recent Developments
5.5 Morphogenesis, Inc
5.5.1 Morphogenesis, Inc Profile
5.5.2 Morphogenesis, Inc Main Business
5.5.3 Morphogenesis, Inc Pet Cancer Therapeutics Products, Services and Solutions
5.5.4 Morphogenesis, Inc Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Morphogenesis, Inc Recent Developments
5.6 VetDC, Inc
5.6.1 VetDC, Inc Profile
5.6.2 VetDC, Inc Main Business
5.6.3 VetDC, Inc Pet Cancer Therapeutics Products, Services and Solutions
5.6.4 VetDC, Inc Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 VetDC, Inc Recent Developments
5.7 Karyopharm Therapeutics, Inc
5.7.1 Karyopharm Therapeutics, Inc Profile
5.7.2 Karyopharm Therapeutics, Inc Main Business
5.7.3 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Products, Services and Solutions
5.7.4 Karyopharm Therapeutics, Inc Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Karyopharm Therapeutics, Inc Recent Developments
5.8 Rhizen Pharmaceutical SA
5.8.1 Rhizen Pharmaceutical SA Profile
5.8.2 Rhizen Pharmaceutical SA Main Business
5.8.3 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Products, Services and Solutions
5.8.4 Rhizen Pharmaceutical SA Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Rhizen Pharmaceutical SA Recent Developments
5.9 Regeneus Ltd.
5.9.1 Regeneus Ltd. Profile
5.9.2 Regeneus Ltd. Main Business
5.9.3 Regeneus Ltd. Pet Cancer Therapeutics Products, Services and Solutions
5.9.4 Regeneus Ltd. Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Regeneus Ltd. Recent Developments
5.10 Oasmia Pharmaceuticals AB
5.10.1 Oasmia Pharmaceuticals AB Profile
5.10.2 Oasmia Pharmaceuticals AB Main Business
5.10.3 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Products, Services and Solutions
5.10.4 Oasmia Pharmaceuticals AB Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Oasmia Pharmaceuticals AB Recent Developments
5.11 Zoetis
5.11.1 Zoetis Profile
5.11.2 Zoetis Main Business
5.11.3 Zoetis Pet Cancer Therapeutics Products, Services and Solutions
5.11.4 Zoetis Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Zoetis Recent Developments
5.12 VetiVax
5.12.1 VetiVax Profile
5.12.2 VetiVax Main Business
5.12.3 VetiVax Pet Cancer Therapeutics Products, Services and Solutions
5.12.4 VetiVax Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 VetiVax Recent Developments
5.13 Ngelheim International GmbH
5.13.1 Ngelheim International GmbH Profile
5.13.2 Ngelheim International GmbH Main Business
5.13.3 Ngelheim International GmbH Pet Cancer Therapeutics Products, Services and Solutions
5.13.4 Ngelheim International GmbH Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Ngelheim International GmbH Recent Developments
5.14 Elanco
5.14.1 Elanco Profile
5.14.2 Elanco Main Business
5.14.3 Elanco Pet Cancer Therapeutics Products, Services and Solutions
5.14.4 Elanco Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Elanco Recent Developments
5.15 Merial Inc
5.15.1 Merial Inc Profile
5.15.2 Merial Inc Main Business
5.15.3 Merial Inc Pet Cancer Therapeutics Products, Services and Solutions
5.15.4 Merial Inc Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Merial Inc Recent Developments
5.16 ELIAS Animal Health
5.16.1 ELIAS Animal Health Profile
5.16.2 ELIAS Animal Health Main Business
5.16.3 ELIAS Animal Health Pet Cancer Therapeutics Products, Services and Solutions
5.16.4 ELIAS Animal Health Pet Cancer Therapeutics Revenue (US$ Million) & (2018-2023)
5.16.5 ELIAS Animal Health Recent Developments
6 North America
6.1 North America Pet Cancer Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Pet Cancer Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pet Cancer Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pet Cancer Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pet Cancer Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pet Cancer Therapeutics Market Dynamics
11.1 Pet Cancer Therapeutics Industry Trends
11.2 Pet Cancer Therapeutics Market Drivers
11.3 Pet Cancer Therapeutics Market Challenges
11.4 Pet Cancer Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
